Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Inventory (2022 - 2025)

Axsome Therapeutics' Inventory history spans 3 years, with the latest figure at $15.7 million for Q4 2024.

  • For Q4 2024, Inventory rose 3.94% year-over-year to $15.7 million; the TTM value through Dec 2024 reached $15.7 million, up 3.94%, while the annual FY2024 figure was $15.7 million, 3.94% up from the prior year.
  • Inventory for Q4 2024 was $15.7 million at Axsome Therapeutics, up from $15.2 million in the prior quarter.
  • Across five years, Inventory topped out at $15.7 million in Q4 2024 and bottomed at $4.3 million in Q4 2022.
  • The 3-year median for Inventory is $15.1 million (2023), against an average of $12.1 million.
  • The largest annual shift saw Inventory skyrocketed 250.35% in 2023 before it increased 3.94% in 2024.
  • A 3-year view of Inventory shows it stood at $4.3 million in 2022, then surged by 250.35% to $15.1 million in 2023, then increased by 3.94% to $15.7 million in 2024.
  • Per Business Quant, the three most recent readings for AXSM's Inventory are $15.7 million (Q4 2024), $15.2 million (Q2 2024), and $15.1 million (Q4 2023).